Skip to content
Citation only via OpenAlex

PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION

Marco A. Zarbin, Philip J. Rosenfeld

Retina · 2010 · ▲ 140 citations

Abstract

In Brief Purpose: To review treatments under development for age-related macular degeneration (AMD) in the context of current knowledge of AMD pathogenesis. Methods: Review of the scientific literature published in English. Results: Steps in AMD pathogenesis that appear to be good targets for drug development include 1) oxidative damage; 2) lipofuscin accumulation; 3) chronic inflammation; 4) mutations in the complement pathway; and 5) noncomplement mutations that influence chronic inflammation and/or oxidative damage (e.g., mitochondria and extracellular matrix structure). Steps in neovascularization that can be targeted for drug development and combination therapy include 1) angiogenic factor production; 2) factor release; 3) binding of factors to extracellular receptors (and activation of intracellular signaling after receptor binding); 4) endothelial cell activation (and basement membrane degradation); 5) endothelial cell proliferation; 6) directed endothelial cell migration; 7) extracellular matrix remodeling; 8) tube formation; and 9) vascular stabilization. Conclusion: The era of pathway-based therapy for the early and late stages of AMD has begun. At each step in the pathway, a new treatment could be developed, but complete inhibition of disease progression will likely require a combination of the various treatments. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefits (visual acuity and frequency of treatment) will likely be superior to monotherapy in preventing the late-stage complications of AMD. The era of pathway-based therapy for the early and late stages of AMD has begun. At each step in the pathway, a new treatment could be developed, but complete inhibition of disease progression will likely require a combination of the various treatments. Combination therapy will likely supplant monotherapy as the treatment of choice because the clinical benefi ts (visual acuity and frequency of treatment) will likely be superior to monotherapy in preventing the late-stage complications of AMD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1097/iae.0b013e3181f57e30
Canonical
link ↗
Fetched
2026-10-19 MST

Cite this

APA
Zarbin, M.A., &amp; Rosenfeld, P.J. (2010). PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION. <em>Retina</em>. https://doi.org/10.1097/iae.0b013e3181f57e30
Vancouver
Zarbin MA, Rosenfeld PJ. PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION. Retina. 2010. doi:10.1097/iae.0b013e3181f57e30.
BibTeX
@article{marco2010PATHWA, title = {PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION}, author = {Marco A. Zarbin and Philip J. Rosenfeld}, journal = {Retina}, year = {2010}, doi = {10.1097/iae.0b013e3181f57e30}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings